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ABSTRACT

The present invention provides methods for reducing, reversing or inhibiting neovascularization in a tissue of a mammalian subject having a pathological condition involving
neovascularization by administration in vivo of nanoceria
particles (cerium oxide nanoparticles) to the subject. The
method of the invention is useful, for example, for reducing,
treating, reversing or inhibiting neovascularization in ocular
tissue such as the retina, macula or cornea; in skin; in synovial
tissue; in intestinal tissue; or in bone. In addition, the method
of the invention is useful for reducing or inhibiting neovascularization in a neoplasm (tumors), which can be benign or
malignant and, where malignant, can be a metastatic neoplasm. As such, the invention provides compositions, which
contain nanoceria particles and are useful for reducing, treating, reversing or inhibiting angiogenesis in a mannnalian
subject.
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INHIBITION OF NEOVASCULARIZATION BY
CERIUM OXIDE NANOPARTICLES

abnormal migration and proliferation of endothelial cells into
tissues of the eye. Such neovascularization in ocular tissues
can induce corneal scarring, retinal detachment and fluid
accumulation in the choroid, each of which can adversely
affect vision and lead to blindness.
Angiogenesis also is associated with the progression and
exacerbation of inflammatory diseases, including psoriasis,
rheumatoid arthritis, osteoarthritis, and inflammatory bowel
diseases such as ulcerative colitis and Crohn's disease. In
inflammatory arthritic disease, for example, influx of lymphocytes into the region surrounding the joints stimulates
angiogenesis in the synovial lining. The increased vasculature provides a means for greater influx of leukocytes, which
facilitate the destruction of cartilage and bone in the joint.
Neovascularization that occurs in inflammatory bowel disease results in similar effects in the bowel.
The growth of capillaries into atherosclerotic plaques in the
coronary arteries represents another pathological condition
associated with growth factor induced angiogenesis. Excessive blood flow into neovascularized plaques can result in
rupture and hemorrhage of the blood-filled plaques, releasing
blood clots that can result in coronary thrombosis.
The involvement of angiogenesis in such diverse diseases
as cancer, ocular disease and inflammatory diseases has led to
an effort to identify methods for specifically inhibiting angiogenesis as a means to treat these diseases. For cancer patients,
such methods of treatment can provide a substantial advantage over currently used methods such as chemotherapy,
which kill or impair not only the target tumor cells, but also
normal cells in the patient, particularly proliferating normal
cells such as blood cells, epithelial cells, and cells lining the
intestinal lumen. Such non-specific killing by chemotherapeutic agents results in side effects that are, at best, unpleasant, and can often result in unacceptable patient morbidity, or
mortality. In fact, the undesirable side effects associated with
cancer therapies often limit the treatment a patient can
receive.
For other pathological conditions associated with abnormal angiogenesis such as diabetic retinopathy, there are no
effective treatments short of retinal transplants. However,
even if retinal transplantation is performed, the new retina
would be subject to the same conditions that resulted in the
original retinopathy. Thus, there exists a need for novel methods of inhibiting and treating neovascularization in patients
suffering from pathological conditions characterized by this
condition. The present invention satisfies this need and provides related advantages as well in the treatment of other
disease conditions identified herein.
The retina is the part of the eye that is sensitive to light. The
macula lutea is the region of the retina that allows us to read
and recognize faces. Diseases of the macula, such as agerelated macular degeneration (AMD) and diabetic macular
edema, account for a major proportion of legal blindness. To
combat these diseases, a variety of accepted and experimental
medications are employed via systemic routes or local, invasive surgical procedures.
Diabetic retinopathy (DR), a leading cause of blindness in
type 1 and type 2 diabetics, is a complication of diabetes
which produces damage to the blood vessels inside the retina.
Diabetic retinopathy can have four stages: (1) mild nonproliferative retinopathy, wherein microaneurysms in the retina's blood vessels occur; (2) moderate nonproliferative retinopathy, wherein some blood vessels feeding the retina
become blocked; (3) severe nonproliferative retinopathy,
wherein many blood vessels to the retina are blocked, depriving several areas of the retina with their blood supply; and (4)
proliferative retinopathy, wherein new, abnormal, thin-

CROSS-REFERENCE TO RELATED
APPLICATIONS
The present application claims the benefit under 35 U.S.C.
119(e) of U.S. Provisional Application Ser. No. 61/125,602,
filed Apr. 25, 2008, the entirety of which is hereby expressly
incorporated herein by reference.
The present application is also a continuation-in-part of
U.S. Ser. No. 11/412,665, filed Apr. 27, 2006, now U.S. Pat.
No. 7,727,559 issued on Jun. 1, 2010, which claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application
Ser. No. 60/716,630, filedSep.13, 2005, and U.S. Provisional
Application Ser. No. 60/676,043, filed Apr. 29, 2005.
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Not applicable.
BACKGROUND OF THE INVENTION
Angiogenesis (also referred to herein as neovascularization) is the process whereby new blood vessels are formed.
Angiogenesis occurs normally during embryogenesis and
development, and occurs in fully developed organisms during
wound healing and placental development. In addition,
angiogenesis occurs in various pathological conditions,
including in ocular diseases such as diabetic retinopathy and
macular degeneration due to neovascularization, in conditions associated with tissue inflammation such as rheumatoid
arthritis and inflammatory bowel disease, and in cancer,
where blood vessel formation in the growing tumor provides
oxygen and nutrients to the tumor cells, as well as providing
a route via which tumor cells metastasize throughout the
body. Since millions of people around the world are afflicted
by these diseases, a considerable effort has been made to
understand the mechanisms involved in angiogenesis in the
hope that such an understanding will allow the development
of methods for detecting and inhibiting such undesirable
angiogenesis.
Angiogenesis occurs in response to stimulation by one or
more known growth factors, and also may involve other as yet
unidentified factors. Endothelial cells, which are the cells that
line mature blood vessels, normally do not proliferate. However, in response to an appropriate stimulus, the endothelial
cells become activated and begin to proliferate and migrate
into unvascularized tissue forming new blood vessels. In
some cases, precursor cells can be activated to differentiate
into endothelial cells which form new blood vessels.
Blood vessels are surrounded by an extracellular matrix. In
addition to stimulation by growth factors, neovascularization
depends on interaction of the endothelial cells with the extracellular matrix, as well as with each other. The activation of
endothelial cells by growth factors and the migration into and
interaction with the extracellular matrix and with each other is
dependent on cell surface receptors expressed by the endothelial cells. These cell surface receptors, which include
growth factor receptors and integrins, interact specifically
with particular molecules.
In pathological conditions such as age-related macular
degeneration and diabetic retinopathy, decreasing availability
of oxygen to the retina results in a hypoxic condition that
stimulates the secretion of angiogenic growth factors such as
vascular endothelial growth factors (VEGF), which induce
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walled and fragile-walled blood vessels grow to supply blood
to the retina, but which new blood vessels may leak blood to
produce severe vision loss and blindness. Hemorrhages can
occur more than once, often during sleep. Fluid can also leak
into the center of the macula at any stage of diabetic retinopathy and cause macular edema and blurred vision. About
40 to 45 percent of Americans diagnosed with diabetes have
some stage of diabetic retinopathy, and about half of the
people with proliferative retinopathy also have macular
edema.
Macular degeneration is a degeneration of the macular
region of the retina in the eye. Degeneration of the macula
causes a decrease in acute vision and can lead to eventual loss
of acute vision. The wet form of macular degeneration is
related to abnormal growth of blood vessels in the retina that
can leak blood and can cause damage to photoreceptor cells.
Age-related macular degeneration is a collection of clinically
recognizable ocular findings that can lead to blindness. Macular degeneration is a group of diseases. There are two basic
types of macular degeneration, including "wet" and "dry". In
wet macular degeneration, there is an abnormal growth of
new blood vessels (neovascularization). These new blood
vessels break and leak fluid, causing damage to the central
retina. This form of macular degeneration is often associated
with aging. Approximately 85% of macular degeneration
cases are dry macular degeneration. Vision loss can result
from the accumulation of deposits in the retina called druzen,
and from the death of photoreceptor cells in the retina. This
process can lead to thinning and drying of the retina.
The findings of AMD include the presence of druzen, retinal pigment epithelial disturbance, including pigment clumping and/or dropout, retinal pigment epithelial detachment,
geographic atrophy, subretinal neovascularization and disciform scar. Age-related macular degeneration is a leading
cause of presently incurable blindness, particularly in persons
over 55 years of age. Approximately one in four persons age
65 or over have signs of age-related maculopathy, and about
7% of persons age 75 or over have advanced macular degeneration with vision loss.
Druzen are opthalmoscopically visible, yellow-white hyaline excrescences or nodules ofBruch's membrane. Bruch's
membrane lies beneath the retina and the adjacent retina
pigment epithelium layer. Fat accumulates in Bruch's membrane with age and may contribute to the formation of druzen.
Druzen can occur in two forms. One form comprises hard,
small (less than about 60 micrometers in diameter) objects
which do not increase with age and which do not predispose
to macular degeneration. Another form comprises soft, large
(more than about 63 micrometers in diameter) objects which
enlarge and become confluent with age. The soft, large druzen
may predispose to macular degeneration, and are commonly
seen in eyes of people with advanced macular degeneration in
at least their other eye.
Druzen may be metabolic waste products from various
layers of the retina such as from the retina, retina pigment
epithelium, and choriocapillaris. Druzen may be yellow,
white, gray, retractile, and/or pink. Druzen may be small,
medium or large in size. Druzen may be regular or irregular,
or symmetrical or asymmetrical in shape. A patient who has
druzen and who suffers complications in one eye may suffer
no complications in the other eye. Complications may comprise one or more conditions selected from the group consisting of retina pigment epithelium atrophy, choroid neovascularization, retina detachment serous, and retina detachment
hemorrhagic. Druzen may affect contrast sensitivity, and may
reduce the eye's ability to see sufficiently to allow a person to

read in dim light or to see sufficient detail to permit a person
to drive an automobile safely at night.
A contributing and indicating factor of advanced macular
degeneration is neovascularization of the choroid tissue
underlying the photoreceptor cells in the macula. Healthy
mature ocular vasculature is normally quiescent and exists in
a state of homeostasis in which a balance is maintained
between positive and negative mediators of angiogenesis in
development of new vasculature. Macular degeneration, particularly in its advanced stages, is characterized by the pathological growth of new blood vessels in the choroid underlying
the macula. Angiogenic blood vessels in the subretinal choroid can leak vision obscuring fluids, leading to blindness.
The major causes of blindness in the United States are
glaucoma, AMD, cataracts, DR, and retinitis pigmentosa
(RP) which translates into more than 38 million citizens having some form of an age related eye disease. In developed
countries, cataracts are routinely surgically removed and
vision is restored with the insertion of an artificial lens. There
are no cures for most forms of the other blinding diseases, the
severity of which increases with age and dramatically
decreases the quality of life for these patients. Even for
patients with an inherited blindness, such as RP, vision worsens with age. Nearly 1 out of3 individuals over the age of75
will develop some form of AMD and with the aging of the
"Baby Boomers" generation, this means a dramatic increase
in patient numbers. Nearly 200,000 individuals in the USA
develop AMD each year. About 2 million Americans over the
age of 40 have significant vision loss due to AMD while an
additional 8 million have a high risk of vision loss. DR has
some symptoms very similar to wet AMD including neovascular growth in the eye and sub foveal macular edema. About
4 million Americans age 40 and older have DR and >80% of
patients who have diabetes for more than ten years will
develop DR. Further, because Native American Indians
develop diabetes at a much higher rate than the general population, DR is becoming a progressively increasing problem in
states such as Oklahoma which have large numbers of Native
Americans. The annual economic cost to the USA for adult
vision loss is major at about $50 billion per year.
As noted above, AMD is classified roughly into two categories based on the absence or presence of choroidal neovascularizations which grow into the eye. Most patients have the
dry form (85%) whereas about 15% have the wet form. The
dry form is characterized by the accumulation of debris
(druzen) between the retinal pigment epithelia and Bruch's
membrane which effectively eliminates the benefits of the
choroidal blood supply to the adjacent photoreceptor cells.
The dry form can lead to the wet form, but optionally may not,
and patients may still retain some retinal function throughout
life. In the wet form, the presence of sub-macular neovascular
vessels leads to retinal edema, ruptured blood vessels, the
death of the cones in the macula and eventual blindness.
Current therapeutic treatments for wet AMD involve intravitreal injections of monoclonal antibodies against Vascular
Endothelial Growth Factor (VEGF) every 6-8 weeks. There
are no treatments which have proven successful for dry AMD.
Recently, a subform of AMD was recognized, called Retinal
Angiomatous Proliferation (RAP), in which neovascular
lesions occurred within the photoreceptor cell layer as a result
of neovessels growing from the retinal vasculature through
the photoreceptors, the RPE and Bruch's membrane where
they joined choroidal neovascular tufts. These patients represent about 15% of the vascular form ofAMD. It is an object of
the present invention to develop a therapeutic treatment for
blinding diseases, such as RAP.
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Mammalian cells produce cellular energy in mitochondria
by using oxygen to metabolize molecular substrates. The vast
majority of the products of this oxidative metabolism are
beneficial while about 3% are highly toxic compounds such
as singlet oxygen, the hydroxide ion, and hydrogen peroxide.
These Reactive Oxygen Species (ROS) can react with and
damage almost any type of molecule within the cell including
proteins, DNA, RNA and lipids. Another major source of
intracellular ROS is NADPH oxidase which activates the
STAT3 pathway which upregulates retinal VEG F. The normal
antioxidant cellular defenses against ROS include catalytic
proteins such as superoxide dismutase, heme oxygenase and
thioredoxin as well as small molecules like glutathione, and
NADPH. Oxidative stress occurs when the level of ROS
exceeds the ability of the cells' antioxidant defenses to scavenge or destroy them. Because of the close proximity of the
intra-mitochondrial components to the ROS, it is not surprising that they bear the brunt of damage from ROS and with
decreased oxidative phosphorylation they produce less
energy but more ROS.
As indicated herein, there are many diseases which result
in the programmed cell death of photoreceptor cells and
blindness. These include illnesses which are known to be
inherited such as retinitis pigmentosa as well as many which
have a genetic component but which may be environmentally
induced or are of questionable origin such as diabetic retinopathy and AMD. Interestingly, irrespective of the primary
cause, all of these diseases are thought to share some common
nodes, including oxidative stress caused by a chronic or acute
rise in ROS and apoptosis. The retina has the highest rate of
oxygen metabolism, is constantly bombarded with photons of
light, and is therefore exposed to a higher concentration of
ROS than any other tissue of the body. Neurodegeneration
within the retina is not unlike neurodegeneration within other
areas of the central nervous system. Even in the albino rat
model of light-induced degeneration of photoreceptor cells,
initiation of apoptosis proceeds through the intracellular production of ROS. Strong evidence that oxidative damage is a
primary cause of AMD was recently presented by Hollyfield
et al. ("Oxidative damage-induced inflammation initiates
age-related macular degeneration', Nat. Med. 2008; 14: 194198).

FIG. 9 is a graph showing that nanoceria downregulate
VEGF in mature VLDLr KO retinas.

BRIEF DESCRIPTION OF THE DRAWINGS
FIG.1 shows photomicrographs of results from four assays
for ROS and ROS-induced changes in VLDLr Knock Out
(VLDLr KO) mouse retinas.
FIG. 2 is a schematic showing that nanoceria inhibit the rise
in VEGF in retinas ofVLDLr KO mice. Actin was stained as
a load control.
FIG. 3 shows immunofluorescence confocal photomicrographs of retinas to show localization ofVEGF in retinas and
effects of nanoceria thereon.
FIG. 4 shows micrographs of VLDLr KO retinal layers
which show formation of new blood vessels ("bleb" at arrowheads). These blebs are reduced by nanoceria treatment.
FIG. 5 shows cut and flattened eyecups of normal (C57)
and VLDLr KO mice, with and without treatment with nanocena.
FIG. 6 shows micrographs ofVLDLr KO vascular defects.
FIG. 7 is a graph showing the effects of treatment with
nanoceria on numbers of choroidal tufts.
FIG. 8 is a graph showing that nanoceria treatment causes
regression of retinal vascular lesions which were present prior
to treatment.

DETAILED DESCRIPTION OF THE INVENTION

10

15

20

25

30

35

40

45

50

55

60

65

The present invention provides methods for reducing,
treating, reversing, or inhibiting neovascularization in a tissue
of a mammalian subject having a pathological condition
involving neovascularization by in vivo administration of
nanoceria particles (cerium oxide nanoparticles) in the subject. The method of the invention is useful, for example, for
reducing, treating, reversing or inhibiting neovascularization
in pathological conditions associated with ocular tissue such
as the retina, macula or cornea; in skin; in synovial tissue; in
intestinal tissue; or in bone. In addition, the method of the
invention is useful for reducing, reversing or inhibiting
neovascularization in neoplasms (tumors), which can be
benign or malignant and, where malignant, can be metastatic
neoplasms. As such, the invention provides compositions,
which contain nanoceria particles and are useful for reducing,
reversing, or inhibiting angiogenesis associated with such
pathological condition in a mammalian subject.
The pathological conditions treated by the method of the
invention include, but are not limited to, those of: the eye,
such as diabetic retinopathy or macular degeneration; the
skin, such as a hemangioma or psoriasis; a joint, such as
rheumatoid arthritis or osteoarthritis; or the intestine, such as
Crohn' s disease or ulcerative colitis; or can be a tumor, which
can be benign or malignant.
The present invention further provides methods of reducing, treating, reversing or inhibiting neovascularization (angiogenesis) in a tissue in an individual, by administering to
the individual the nanoceria particles of the invention, thereby
reducing or inhibiting angiogenesis in the tissue in the individual and, consequently, reducing the severity of the pathological condition exhibiting the angiogenesis. The condition
can be any pathological condition associated with angiogenesis, including a neoplasm, which can be a malignant neoplasm, for example, a carcinoma such as breast carcinoma,
colon carcinoma, ovarian carcinoma or pancreatic carcinoma, or a sarcoma, mesothelioma, teratocarcinoma, an
astrocytoma, glioblastoma, or other neoplasm, including a
metastatic malignant neoplasm. The agent can be administered by various routes, for example, intravenously or directly
into the region to be treated, for example, directly into a
neoplastic tumor; via eye drops or intravitreal injection,
where the pathological condition involves the eye; or intrasynovially, where the condition involves a joint, or via other
methods as discussed elsewhere herein.
Without wishing to be bound by theory, it is believed that in
the present invention, the reduction, reversal, or inhibition of
neovascularization in pathological conditions of ocular tissue
such as retina, macula or cornea; of skin such as occurs with
psoriasis; ofsynovial tissue; ofbone; orofintestinal tissue; or
of benign or malignant neoplasms occurs by reducing the
reactive oxygen species (ROS) in the tissue.
The term "pathological condition" is used broadly herein
to mean any abnormal physical or physiological condition
characterized, at least in part, by neovascularization. Such
pathological conditions include neoplasms, ocular diseases
such as diabetic retinopathy and macular degeneration associated with neovascularization, skin diseases such as psoriasis and hemangiomas, gingivitis, arthritic conditions such as
rheumatoid arthritis and osteoarthritis, and inflammatory
bowel diseases.
The term "neoplasm" is used broadly herein to mean any
new, pathological tissue growth. For purposes of the present
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invention, a neoplasm generally results in the formation of a
tumor, which is characterized, in part, by angiogenesis. A
neoplasm can be benign, for example, a hemangioma,
glioma, teratoma, and the like, or can be malignant, for
example, a carcinoma, sarcoma, glioblastoma, astrocytoma,
neuroblastoma, retinoblastoma, and the like. The term
"tumor" is used generally to refer to a benign or malignant
neoplasm, and the term "cancer" is used generally to refer to
a malignant neoplasm, which may or may not be metastatic.
Malignant neoplasms that can be treated using a method of
the invention include, for example, carcinomas such as lung
cancer, breast cancer, prostate cancer, cervical cancer, pancreatic cancer, colon cancer and ovarian cancer; and sarcomas
such as osteosarcoma and Kaposi's sarcoma, provided the
neoplasm is characterized, at least in part, by angiogenesis.
An individual to be treated using a method of the invention
can be any individual exhibiting a neovascularization associated with a pathological condition and, therefore, can be, for
example, a vertebrate such as a mammal, including a human,
other primate, dog, cat, horse, cow, sheep, or goat or any other
mammal, particularly a commercially important animal or a
domesticated animal and any other animal subject to diseases
similar to those described herein.
Treatment using the methods of the present invention is
considered to be successful when adverse clinical signs or
symptoms associated in the subject with the pathological
condition being treated are reduced, reversed, inhibited, or
otherwise ameliorated. A reduction in the severity of a pathologic condition can be detected by various methods, including
routine clinical tests such as blood tests, which can used to
determine relevant enzyme levels or circulating antigen or
antibody; imaging tests, which can be used to detect a
decrease in the growth rate or size of a neoplasm; or an
ophthalmic procedure, which can be used to identify a reduction in the number of blood vessels in the retina of a diabetic
patient. Such clinical tests are selected based on the particular
pathological condition being treated. A reduction in the severity of a pathological condition also can be detected based on
comments made by the patient being treated, for example,
that a patient suffering from arthritis feels less pain or has
greater joint mobility, or that a patient with diabetic retinopathy or with macular degeneration due to neovascularization
can see more clearly, or the like.
The nanoceria particle composition of the invention generally will be in the form of a pharmaceutical composition
comprising the nanoceria particles and a pharmaceutically
acceptable carrier. Pharmaceutically acceptable carriers are
well known in the art and include aqueous solutions such as
physiologically buffered saline or other buffers or solvents or
vehicles such as glycols, glycerol, oils such as olive oil or
injectable organic esters.
The total amount of the nanoceria composition can be
administered to a subject as a single dose, over a relatively
short period of time, or can be administered using a treatment
protocol in which multiple doses are administered over a
more prolonged period of time. The concentration and quantity of the nanoceria required in the treatment protocol
depends on many factors including the age and general health
of the subject as well as the route of administration, the
number of treatments to be administered.
The nanoceria of the present invention which are useful for
reducing or inhibiting angiogenesis or a pharmaceutical composition thereof containing the nanoceria can be used for
treating any pathological condition that is characterized, at
least in part, by neovascularization. The nanoceria can be
administered by various routes including, for example,
parenterally, including intravenously, intramuscularly, sub-

cutaneously, intraorbitally, intracapsularly, intrasynovially,
intraperitoneally, intracistemally or by passive or facilitated
absorption through the skin using, for example, a skin patch
or transdermal iontophoresis. Furthermore, the composition
can be administered by injection, intubation, via a suppository, orally or topically, the latter of which can be passive, for
example, by direct application of an ointment or powder
containing the composition, or active, for example, using a
nasal spray or inhalant. The pharmaceutical composition also
can be incorporated, if desired, into liposomes, microspheres
or other polymer matrices as discussed elsewhere herein.
In one embodiment the present invention comprises therapeutic treatments which eliminate the leaky neovessels, choroidal neovascularization and vascular lesions within the retinas of mammals with RAP and other ocular diseases
characterized by neovascularization. The present therapeutic
regimes also slow the progression of photoreceptor cell death,
for example in all forms of AMD and DR. These treatments
will dramatically improve the quality of life for millions of
Americans and correspondingly reduce the $50 billion annual
economic cost to the USA.
The present invention in particular relates to methods of
treatment of macular degeneration associated with subretinal
neovascularization and a proliferation of neovascular tissue
in the eye of a mammalian subject, and to methods of inhibiting or substantially reducing the rate of subretinal neovascularization and proliferation of neovascular tissue in the eye
associated with macular degeneration.
The present invention also relates to methods of treatment
of diabetic neuropathy, especially diabetic retinopathy associated with neovascularization, and to methods of inhibiting
or substantially reducing the rate of proliferation of neovascular tissue in the eye associated with diabetic neuropathy
Examples of cerium oxide nanoparticles that may be used
in the present invention include, but are not limited to, those
described in U.S. Pat. Nos. 7,347,987 and 7,504,356 (each of
which are expressly incorporated by reference herein) and
include, but are not limited to, cerium oxides having the
formulas Ce0 2 and Ce 2 0y
The nanoceria particles of the composition are administered in one embodiment at concentrations of 1 nM to 1000
µM, or from 1 nM to 100 µM, or from 1 nM to 10 µM, or from
1 nM to 1 µM, or from 1 nM to 100 nM, or from 1 nM to 50
nM, or from 1 nM to 10 nM, or from 10 nM to 10 µM, or from
100 nM to 10 µM. More particularly, the cerium oxide particles of the present invention are further characterized as
ultra-fine and are preferably in a size range of from approximately 1 nanometer in diameter to approximately 10 nanometers in diameter; more preferably from approximately 1 nm
to approximately 7 nm.
Examples of various methods of administering therapeutic
compositions to the eye, and which may be used to administer
the nanoceria of the present invention, are described, for
example, in U.S. Pat. No. 7,442,686, the entirety of which is
hereby expressly incorporated herein by reference.
For example, the nanoceria particles may be administered
by direct injection into the eye, intravenous, intraperitoneal,
intramuscular, oral or topically on the eye or skin. The nanoceria will reduce damage to the eye caused by angiogenesis
ocular pathological conditions including, but not limited to,
glaucoma, diabetic retinopathy, inherited retinal degeneration (for example, RP), AMD, retinal detachment or any
disease or event which involves production of ROS, neovascularization, for example, including retinopathy of prematurity (ROP), neovascular glaucoma, macular edema, Sickle
Cell retinopathy, choroidal neovascularization, retinal vascu-
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lar diseases, and ocular oncology. These particles will preserve and prolong vision when administered in vivo.
Administration of the nanoceria compositions of this
invention is preferably by injection, such as by injection into
an eye, preferably into a blood vessel that supplies blood to
the eye or by microinjection into the macula by first penetrating the sclera, by topical application such as to a tissue of the
eye such as the cornea or sclera, or by implantation such as by
controlled release from a depot or implant comprising a pharmaceutically acceptable matrix or pharmaceutically acceptable carrier, which depot or implant is located proximal to the
tissue of the eye, preferably proximal to or embedded into
tissue comprising the posterior portion of the eye. A therapeutically effective amount of the composition ofthis invention can be delivered to the choroid and retina proximal to the
macula of the eye to retard the growth of blood vessels that
lead to macular degeneration in the eye.
In one aspect, therapeutic compositions of this invention
can be administered to the eye or other areas of the body by a
number of techniques including by use of medical devices
and methods of administration known in the art, such as for
example those described in U.S. Pat. Nos. 6,397,849; 6,299,
895; 5,770,589; 5,767,079; 5,707,643; 5,632,984; 5,443,505;
5,399,163; 5,383,851; 5,273,530; 5,064,413; 4,941,880;
4,790,824; 4,596,556; 4,487,603; 4,486,194; 4,475,196;
4,447,224; 4,447,233; and 4,439,196, each of which is
expressly incorporated herein by reference in its entirety.
Many other methods of administration such as a single or
multiple implant and/or biodegradable matrix composition
for controlled release the nanoceria of this invention, an
implantable hydrogel matrix which can be biodegradable, an
injectable delivery system such as a liposome suspension,
injection methods such as comprising a needle less syringe or
cannula or needle and syringe, poorly water soluble and biodegradable carriers, and delivery routes that are applicable to
administer a drug to the eye and to blood vessels that feed
blood to the eye can be used with the compositions of this
invention.
For example, the present invention can be delivered by a
variety of techniques to the macula region of the eye, preferably to the posterior segment of the eye proximal to the
macula. Examples of such techniques include: (a) use of a
sterile, pharmaceutically acceptable biodegradable scleral
plug which comprises nanoceria and optionally a pharmaceutically acceptable biodegradable matrix such as a polylactic
acid or polyglycolic acid or a copolymer of lactic acid and
glycolic acid, which plug can be inserted into the eye via an
incision in the sclera; (b) use of an implant comprising nanoceria of this invention and optionally a pharmaceutically
acceptable biodegradable matrix wherein the sclera is cut to
expose the suprachoroid and wherein the implant is placed
into a suprachoroidal space from which implant the nanoceria
are released, for example, into the vitreous region of the eye;
(c) use of intravitreal injection into the vitreous body of a
pharmaceutical composition comprising nanoceria and asterile aqueous carrier; (d) injection or infusion via a flexible
cannula that can be inserted through the posterior sclera and
down into the subretinal space at the posterior region of the
eye; and (e) by injection of a pharmaceutical composition
comprising nanoceria and a pharmaceutically acceptable carrier into an avascular region of the sclera to form a depot
comprising nanoceria within the scleral layer and from which
the nanoceria can diffuse to the macula, choroid layer, and/or
retina.
In one aspect, a pharmaceutical compositions used in the
present invention can comprise a pharmaceutically acceptable carrier selected from the group consisting of poly(ethyl-

ene-co-vinyl acetate), PVA, partially hydrolyzed poly(ethylene-co-vinyl acetate), poly(ethylene-co-vinyl acetate-covinyl alcohol), a cross-linked poly(ethylene-co-vinyl
acetate), a cross-linked partially hydrolyzed poly(ethyleneco-vinyl acetate), a cross-linked poly(ethylene-co-vinyl
acetate-co-vinyl alcohol), poly-D,L-lactic acid, poly-L-lactic
acid, polyglycolic acid, PGA, copolymers of lactic acid and
glycolic acid, polycaprolactone, polyvalerolactone, poly(anhydrides), copolymers of polycaprolactone with polyethylene glycol, copolymers of poly lactic acid with polyethylene
glycol, polyethylene glycol; fibrin, Gelfoam™ (which is a
water-insoluble, off-white, nonelastic, porous, pliable gel
foam prepared from purified gelatin and water for injection),
and combinations and blends thereof. Copolymers can comprise from about 1% to about 99% by weight of a first monomer unit such as ethylene oxide and from 99% to about 1% by
weight of a second monomer unit such as propylene oxide.
Blends of a first polymer such as gelatin and a second polymer
such as poly-L-lactic acid or polyglycolic acid can comprise
from about 1% to about 99% by weight of the first polymer
and from about 99% to about 1% of the second polymer.
The term "pharmaceutically acceptable carrier" or "adjuvant" and "physiologically acceptable vehicle" and the like
are to be understood as referring to an acceptable carrier or
adjuvant that may be administered to a subject, together with
nanoceria ofthis invention. Further, as used herein "pharmaceutically acceptable carrier" or "pharmaceutical carrier" are
known in the art and include, but are not limited to, 0.01-0.1
M solutions and preferably 0.05 M phosphate buffer, or 0.8%
saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions,
and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as
olive oil, and injectable organic esters such as ethyl oleate.
Aqueous carriers include water, alcoholic/aqueous solutions,
emulsions or suspensions, including saline and buffered
media. Parenteral vehicles include sodium chloride solution,
Ringer's dextrose, dextrose and sodium chloride, lactated
Ringer's or fixed oils. Intravenous vehicles include fluid and
nutrient replenishers, electrolyte replenishers such as those
based on Ringer's dextrose, and the like. Preservatives and
other additives may also be present, such as, for example,
antimicrobials, antioxidants, collating agents, inert gases and
the like.
In addition, the term "pharmaceutically effective amount"
or "therapeutically effective amount" refers to an amount of
nanoceria (dose) effective in treating a patient, having, for
example, a site of neovascularization. It is also to be understood herein that a "pharmaceutically effective amount" may
be interpreted as an amount giving a desired therapeutic
effect, either taken in one dose or in any dosage or route or
taken alone or in combination with other therapeutic agents.
Advanced wet AMD is a disease of the eye which comprises neovascularization of the choroid tissue underlying the
photoreceptor cells in the macula. As noted above, AMD,
particularly in its advanced stages, is characterized by the
pathological growth of new blood vessels in the choroid
underlying the macula. Angiogenic blood vessels in the subretinal choroid can leak vision obscuring fluids, leading to
blindness.
In one aspect, diseases of the eye which exhibit neovascularization proximal to the retina such as wet AMD, retinitis
pigmentosa, Stargardt' s Disease, diabetic retinopathy, hypertensive retinopathy, and occlusive retinopathy can be treated
to reduce the rate of neovascularization by administration of
a composition of this invention comprising nanoceria having
angiogenesis inhibiting activity.
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The compositions of the present invention when administered to the eye or to blood vessels that feed into the eye of a
patient can be useful to treat ocular diseases such as, but not
limited to, wetAMD, RP, Stargardt's Disease, DR, hypertensive retinopathy, and occlusive retinopathy by reducing the
rate of formation ofneovascularization and thereby slow the
progress of the disease. The rate of neovascularization which
occurs in such a disease in a patient is preferably reduced by
administration of the nanoceria of this invention to 90%, more
preferably to 50%, even more preferably to 25%, even more
preferably to 10%, even more preferably to 5%, even more
preferably to 1%, and most preferably to 0.1 % or less of the
rate of neovascularization which occurs in such a disease in
the absence of administration of the nanoceria of this invention (i.e., in an untreated patient).
Administration of a pharmaceutical composition comprising the nanoceria of this invention to a subject in need of
treatment for a disease of the eye such as macular degeneration, retinitis pigmentosa, Stargardt's Disease, diabetic retinopathy, hypertensive retinopathy, and occlusive retinopathy
can substantially reduce or prevent angiogenesis associated
with subretinal neovascularization, choroid neovascularization underlying the macula, and a proliferation of neovascular
tissue in the subretinal choroid proximal to the macula in an
eye in a mammalian subject.
The method can be useful as a prophylactic treatment to
prevent further onset or progression of macular or retinal
degeneration in an eye that exhibits symptoms of a disease of
the eye such as macular degeneration, retinitis pigmentosa,
Stargardt's Disease, diabetic retinopathy, hypertensive retinopathy, and occlusive retinopathy. In another aspect, the
method can be useful as a prophylactic treatment to prevent
the deposition of druzen and the death of photoreceptor cells
in the macula or elsewhere in the retina. In one aspect of the
invention, the method can prevent the death of photoreceptor
cells (which photoreceptor cells are also herein referred to as
photoreceptors) in the eye of a subject by acting on intracellular mechanisms of the regulation of cell death. The method
can also be useful to prevent onset or progression of macular
degeneration in an eye that does not exhibit vision-obscuring
symptoms of macular degeneration, especially in an eye of a
patient whose other eye does exhibit vision-obscuring symptoms of macular degeneration.
In another aspect of this invention, a method of treatment of
a disease of the eye such as macular degeneration, retinitis
pigmentosa, Stargardt' s Disease, diabetic retinopathy, hypertensive retinopathy, and occlusive retinopathy comprises
administration such as by injection or implantation (or other
method described herein) into tissue proximal to the eye of a
therapeutically effective amount of nanoceria of this inventi on, or of a sterile pharmaceutical composition of this invention suitable for injectable administration and comprising
nanoceria of this invention and a carrier suitable for injectable
use (e.g., sterile, sterilizable, and isotonic with blood), which
can prevent or delay the onset of angiogenesis associated with
subretinal neovascularization, choroid neovascularization
underlying the macula, and a proliferation of neovascular
tissue in the subretinal choroid proximal to the macula in an
eye of a patient.
The invention further comprises a combination therapy
wherein a VEGF inhibitor may be administered in combination with the present nanoceria therapy. The nanoceria may be
administered with a cytotoxic agent, a chemotherapeutic
agent or a growth inhibitory agent can be administered to the
subject together in a single dosage composition such as a
combined formulation, or each agent can be administered in
a separate dosage formulation. Where separate dosage for-

mulations are used, the nanoceria of the invention and one or
more additional agents can be administered concurrently, or
at separately staggered times, i.e., sequentially. The therapeutic methods of the invention may also be combined with other
agents or medical procedures used for treatment of eye disorders or other pathological conditions expressing neovascularization.
Nanoceria particles are contemplated herein for use in
preventing blindness due to a variety of diseases including,
but not limited to, macular degeneration, hereditary retinitis
pigmentosa, glaucoma, diabetes, and retinal detachment.
Investigations of nanocrystalline cerium oxide (e.g., Ce0 2
and Ce 2 0 3 ) nanoparticles (nanoceria) have revealed that its
lattice constant increases with decreasing nanoparticle size.
This has been attributed to an increase in oxygen vacancies in
the crystal structure. This suggests that the migration
enthalpy of the oxygen vacancy in Ce0 2 is smaller at the
nanoscale. Additionally, at the nanoscale, the surface area of
Ce0 2 particles is dramatically enlarged in relation to its volume which increases oxygen exchange and redox reactions.
Thus, oxygen vacancies are likely to form more readily at the
nano scale.
It is believed that nanoceria, owing to their chemical and
physical structure, can protect cells from ROS or free-radicalinduced damage. This is especially supported by the demonstration that nanoceria have catalytic activities like those of
two major anti-oxidative enzymes, super oxide dismutate and
catalase. The "defects" in the nanoceria particles can act as
chemical spin traps similar to nitrosone compounds, currently used as biological antioxidants. It is believed that the
nanoceria act as free-radical scavengers by switching
between the +3 and +4 valence states via various surface
chemical reactions and one Ce0 2 nanoparticle may offer
many sites of spin-trap activity, whereas current pharmacological agents offer only a few per molecule. Additionally, the
lattice defects in nanoceria can regenerate and do not necessarily require repetitive dosages as seen with the use of
dietary supplements of antioxidants such as vitamins C and E.
It was previously demonstrated that the intravitreal injection
of nanoceria, which catalytically scavenge ROS, prevents
light damage and blindness in albino rats. Herein we demonstrate (as described below) that nanoceria catalytically
destroy ROS in the retinas ofVLDLr Knock Out mice which
in tum prevent oxidative stress and ROS induced damage
such as increases in VEGF, choroidal neovascularization,
retinal vascular lesions, degeneration of photoreceptor cells
and the subsequent loss of vision.
Experimental
The VLDLr KO Mouse Model:
The Very Low Density Lipid Receptor Knock Out mouse
(VLDLr KO), (see Heckenlively et al., "Mouse model of
subretinal neovascularization with choroidal anastomosis".
Retina 2003; 23: 518-522), is an outstanding animal model
for AMD and in particular for RAP (Retinal Angiomatous
Proliferation) in which there is a progressive increase in retinal VEGF and VEGF-induced vascular proliferation within
the photoreceptor cell outer nuclear layer as well as an accumulation of lipid particles with degeneration of Bruch's
membrane. This mouse also exhibits subretinal choroidal
neovascularization. Oxidative stress in the VLDLr KO mouse
has also been shown to be associated with a low antioxidant
capacity in its mitochondria. The overall phenotype is very
similar to that associated with a subset of AMD patients who
have Retina Angiomatous Proliferation (RAP). VEGF is
responsible for angiogenesis and vasculature formation in the
eye and numerous strategies have been designed to inhibit its
activity in many diseases, including AMD and cancer. Cur-
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rently, the only effective therapy for wet AMD is the intravitreal injection, every 4-6 weeks, of monoclonal antibodies
against VEGF, aptamers which inhibit VEGF activity or
soluble receptors for VEGF which act as "VEGF traps". Our
recently published data (Li et al., "Biochemical alterations in
the retinas of very low-density lipoprotein receptor knockout
mice: an animal model of retinal angiomatous proliferation".
Arch Opthalmol 2007; 125: 795-803), demonstrated the rise
in VEGF in the ONL of the retina, the developmental increase
in illicit blood vessels and the increase in pro-inflammatory
enzymes prior to vascularization. We hypothesized herein
that nanoceria, through scavenging of ROS, can inhibit the
rise in VEGF, the subsequent angiogenesis and vascular
lesions in the retina and the eventual photoreceptor cell death.
Data provided herewith support this assertion.
In this mouse model (VLDLr KO) for macular degeneration, blood vessels form and grow from the retinal vasculature
through the choroid and retinal pigment epithelium layer. In
some forms of macular degeneration and in diabetic retinopathy, the retinal blood vessels also become "leaky". As shown
in the data below, administration of nanoceria particles prevents both choroidal neovascularization (CNV) and leakage
of the retinal blood vessels.
We hypothesized that the nanoceria, by a mechanism
involving the elimination of endogenously produced ROS,
inhibit the mutant phenotype of the VLDLR -/-mouse. The
phenotypic characteristics which were measured were: ROS
and ROS-mediated damage in the retina; the illicit rise in
Vascular Endothelial Growth Factor (VEGF); retinal vascular
lesions; subretinal neovascularization; disruption ofBruch's
membrane and the retinal pigment epithelium cell layer by
choroidal neovascular tufts. Quantitative histology, using
bright field microscopy on hematoxylin and eosin (H&E)
stained retinal sections, were used to evaluate the morphological preservation of photoreceptor cells whereas retinal
function was determined using electroretinography. VEGF
levels in the retina were assayed with anti-VEGF immunoblots, ELISAs and immunocytochemistry whereas its mRNA
were assayed by RT-PCR. Superoxide radicals in the retina
were assessed using a hydroxyethidine assay whereas H 2 0 2
were assayed with 2',7'-dichloro-dihydro-fluorescein-diacetate. ROS-induced damage were visualized with antibodies
against products of ROS activity including acrolein, nitrotyrosine and 8-hydroxy-2-deoxy-guanosine. The effects of the
nanoceria on neuroprotective pathways were analyzed by
Western blots and cDNA micro arrays. We have established a
vascular filling assay to visualize both the retinal vasculature
and choroidal neovascularizations. Our new Olympus Zoom
Fluorescence Microscope (MVXlO) for macro to microfluorescence imaging enabled us to perform fluorescein angiography on the same live mouse and follow the development
and/or regression of the choroidal neovascular tufts and the
retinal vascular blebs and lesions on successive days for the
same mouse. A major advantage of our current in vivo assays
is that the data can be obtained within one week.
Effects on ROS and ROS-induced Damage
We first performed experiments to determine ifthere actually was an increase in ROS in the retina of the VLDLr KO
mouse and if the nanoceria could reduce the ROS and the
damage caused by them. In a cell, the three major sources of
intracellular ROS are from 1) mitochondrial oxidative respiration, 2) NADPH-oxidase and 3) Nitrous oxide synthetase
(NOS3). FIG. 1 shows representative data from four different
assays (three mice for each condition for each assay) for ROS
and ROS-induced changes. A single injection of saline or
nanoceria (1 µl of 1 mM nanoceria) was given on P7 (7'h day
after birth) and three weeks later the retinas were collected.

These data demonstrate that ROS and ROS-induced effects
increase in VLDLr KO retinas and that the treatments with
nanoceria decrease these characteristics. All settings for the
fluorescence confocal microscope were constant within each
of the assays.
The dihydrodichlorofluorescein assay (DCF) visualizes
cellular oxidation by hydrogen peroxide, peroxynitrite and
hydroxyl radicals. The data show very low levels of DCF in
the normal retina (Wt p28), high levels ofDCF in the saline
injected VLDLr KO retina (v/v p28) and greatly reduced
levels in the nanoceria (Ce0 2 ) injected VLDLr retina KO.
A major source of intracellular ROS is from the enzyme
NADPH Oxidase. Our data show that the intensity of staining
for its activating subunit, P47, is greatly increased in the
VLDLr KO retina vs the normal control but is reduced almost
to control levels by injection of nanoceria.
Nitrotyrosine is a marker for the intracellular effects of
Nitrous Oxygen Species. Our data show that the VLDLr KO
retina stains very intensely whereas the retinas from control
and nanoceria injected VLDLr KO mice show greatly
reduced staining.
ROS-induced damage to DNA is reflected in the amount of
8-hydroxy-2'-deoxyguanosine (8-0H-dG) present. This
assay requires digestion of the cryostat section with proteinase K which results in poor preservation of retinal morphology. However the data show that the nanoceria reduce the
staining for 8-0HdG in the VLDLr KO retinas to near control
levels.
VEGF-Western Data.
Mice were injected intravitreally with either 1 µl of PBS or
1 ul of PBS plus nanoceria at postnatal P13 and the animals
killed on P21. Retinas were homogenized, subjected to SDSPAGE, and blotted to nitrocellulose. The bands were detected
with primary and secondary antibodies and visualized with an
HRP-DAB assay (FIG. 2). Wild type (+!+)retinas had barely
detectable levels of VEGF with or without nanoceria. The
VLDLr KO retinas had about an eightfold increase in VEGF
compared to the +/+retinas. However, the nanoceria injected
VLDLr KO mice had about 60% less VEGF at day 21. These
data indicate that VEGF increased in the VLDLr KO retinas
due to ROS and that it decreased because of the nanoceria
mediated decrease in ROS.
VEGF-Localization by Immunofluorescence.
To determine where VEGF was localized in the Wild type
and the VLD Lr KO retinas and whether the nanoceria had any
effect on the localization, Alexa green-conjugated secondary
antibodies were used in combination with anti-VEGF primary immunoglobulins. The wild type mouse retinas
(C57BL/6J) (FIG. 3A,B) had very little VEGF and it was
localized to the outer segments of the retina. However, the
pattern oflabeling with anti-VEGF in the VLDLr KO retina
(FIG. 3C,D) was heavy but discontinuous; predominantly in
the outer and inner segments of photoreceptors; and especially in their perinuclear regions in the ONL adjacent to
vascular lesions. The intensity of labeling progressively
diminished as the distance from the lesion increased. The
age-matched VLDLr mice, which had received an intravitreal
injection (1 ul of 1 mM) of nanoceria on P7, had fewer
vascular lesions and exhibited greatly reduced staining surrounding the remaining lesions (FIG. 3. E, F). Individual
"optical sections" reveal uniform labeling of the cytoplasm
surrounding the photoreceptor cell nuclei and inner segments
which suggests that the VLDLr KO photoreceptor cells are
making VEGF. Also, a single injection of the nanoceria at P7
inhibits the developmental increase in retinal VEGF for at
least three weeks. These data demonstrate that the rise in
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retinal VEGF in the VLDLr KO retina is due to ROS and can
be prevented by the scavenging activities of nanoceria.
Nanoceria Inhibit Development of "Neo" Leaky Retinal
Vasculature in VLDLr KO Retinas.
The retina has two blood supplies, the retinal vasculature
and the choroid. The VLDLr KO retina has problems with
both systems. The retinal vasculature of the VLDLr KO
mouse exhibits a developmental increase in "neo" vessels
which are absent from control retinas suggesting the possibility that these vessels arise as a result of the increase in
retinal VEGF and that the nanoceria can inhibit their <levelopment. To test this, we used fluorescein-conjugated Dextran
to visualize the retinal vasculature and asked if an intravitreal
injection of the nanoceria on P7 could inhibitthe formation of
these illicit blood vessels when visualized on P28. Representative images from such an experiment are shown in FIG. 4.
With this assay, the larger vessels in the control C57 retinas
(FIG. 4A) are very bright with the smaller vessels forming a
less intensely labeled meshwork. Injection of nanoceria or
saline has no effect on the normal retinal vasculature so that
data is not shown. The VLDLr KO retinal vessels of saline
injected (FIG. 4B) or uninjected (not shown) mice have
brightly labeled newly formed vessels with coiled ends (appearing as "blebs") which project toward the RPE cells. The
nanoceria injected VLDLr KO eyes (FIG. 4C) show greatly
reduced numbers of these neovessels.
Nanoceria Inhibit Development of Choroidal Neovascular
Tufts.
The vascular filling assay also enables choroidal neovascular connections between the choroid and retina blood supplies to be visualized. In this case, after the retina has been
removed the remaining RPE-sclera-choroid is "pie-cut" to
allow flat mounting and placed with the RPE facing up (FIG.
S). The pigmented RPE prevent visualization of any of the
choroidal vasculature in the normal C57 mouse (FIG. SA) but
the eyecup from the saline injected VLDLr KO mice (FIG.
SB) had numerous bright choroidal neovascular tufts which
projected through the RPE cell layer. However, the eyes of the
VLDLr KO mice which had been injected with nanoceria
(FIG. S C) have far fewer choroidal neovascular tufts.
Vascular Lesions can be Quantified.
Because choroidal neovascular "tufts" and retinal neovascular "blebs" are readily visible, both can be quantified. The
results of such an experiment are presented in FIG. 6 and FIG.
7 and demonstrate that the number of choroidal tufts present
during development increases, especially by P28. The data
also show that a single injection of nanoceria at P7 decreases
the numberof such tufts seen in Pl 4, P21 and P28 VLDLr KO
choroids. The confocal microscope shows the vascular
lesions as "blebs" which are present in significant numbers
even at P14 and progressively increase at P21 and P28. As
with the tufts, the developmental appearance of the blebs is
strongly inhibited by a single injection of nanoceria at P7.
These data strongly support our hypothesis that ROS represents an important connection between the primary defect
and the downstream effects which in the VLDLr KO mouse
are vascular defects. These data also indicate that by counting
blebs and tufts, the effectiveness of a therapeutic treatment
can be evaluated. Therefore, dose response experiments can
be done to determine the lowest dose of nanoceria that is most
effective. This assay also enables a comparative analysis to be
performed between nanoceria and other antioxidant agents.
Regression of Vascular Anomalies by Treatment with
Nanoceria.
Although these data were scientifically very important for
our hypothesis, from a therapeutic perspective, the nanoceria
would be much more useful if they could decrease or elimi-

nate the vascular anomalies which were present prior to their
injection. To examine this possibility, we added an experimental paradigm to that which is seen previously in FIG. 6.
We also asked what would happen to the retinal blebs already
present prior to injection. To answer this, mice were injected
on day 28 and the vascular filling assay was done on day 35.
The P28/35 data are shown in FIG. 8 and indicate that the
retinal vascular lesions, blebs, have slightly increased in the
saline injected mice but in the nanoceria injected mice the
blebs have regressed to the same level as was found on P28
when the mice were injected at P7. Similar data was obtained
when the CNV blobs were counted (data not shown). These
are especially important observations because they indicate
that the vascular blebs and blobs present at the time of injecti on on day 28 are dependent on the presence of ROS and their
downstream effects. Therapeutically this means the nanoceria are effective in subjects which already have vascular
anomalies. These data also indicate that the continued presence of these illicit new blood vessels in the retinal vasculature requires the continual production of ROS and that the
"assay" for therapeutic effects can be done within a week.
In a separate parallel experiment, VEGF was quantified
using densitometry of anti-VEGF bands on immunoblots.
The data (FIG. 9) show that the injection of nanoceria at day
28 into a mature mouse decreases by day 35 to the amount of
retinal VEGF to that found in normal retinas.
Results with this VLDLr KO mouse model are striking.
These data demonstrate that the nanoceria down regulate
retinal VEGF, inhibit the formation of new leaky blood vessels in the retinal vasculature and inhibit choroidal neovascularization. Our assays also enable dose response data to accurately evaluate the effectiveness of different preparations of
nanoceria. In addition, because the nanoceria were also
shown to be therapeutic even when administered after the
illicit retinal vessels have formed, we can now directly compare the efficacy of the nanoceria over time with conventional
treatments using anti-VEGF antibodies which are currently
injected intravitreally every 4-6 weeks for patients with wet
AMD. It is contemplated that nanoceria treatments are effective in macular edema and diabetic retinopathy.
Our data demonstrate four major points. The first is that a
single intravitreal injection of nanoceria into the eyes of
VLDLr KO mice at Postnatal day 7 prevents the inherited
increase in retinal ROS and ROS-mediated damage by a
mechanism involving the inhibition of hypoxia. Our data
show that the three major intracellular sources of ROS which
are elevated by hypoxia, (NADPH oxidase, mitochondrial
oxidative respiration and nitrous oxide synthetase) have
decreased production of ROS in the presence of the nanoceria. Secondly, our data show that the nanoceria, by decreasing ROS, also decrease the downstream effects of ROS
including: preventing the rise in concentration of retinal
VEGF, the development of illicit angiogenesis within the
retinal vasculature and the development of choroidal neovascularization (CNV). The third major point is that when the
nanoceria are injected at postnatal day 28, all of the disease
characteristics which are present at P28 significantly regress
(-80%) within one week. This fact provides us with an assay
of relatively short duration (1 week) which enables the effectiveness of nanoceria preparations to be evaluated within one
week. Fourth, and most important, regarding the present
invention, these data demonstrate that VEGF and illicit vessels, present prior to administration of nanoceria decrease and
regress when nanoceria are injected. This means that the illicit
vessels require ROS. The normal vessels are not affected.
This latter point is extremely important with respect to the
therapeutic treatment of patients with RAP, AMD, diabetic
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retinopathy or any other ROS dependent disease because
illicit blood vessels in their eyes preferably regress after treatment with the nanoceria without any negative effects on the
normal vasculature.
Although the present invention and its advantages have
been described in detail, it should be understood that various
changes, substitutions and alterations can be made herein
without departing from the spirit and scope of the invention as
defined by the appended claims. Moreover, the scope of the
present application is not intended to be limited to the particular embodiments of the process, compositions of matter,
means, methods and steps described in the specification. As
one of ordinary skill in the art will readily appreciate from the
disclosure of the present invention, processes, compositions
of matter, means, methods, or steps, presently existing or later
to be developed that perform substantially the same function
or achieve substantially the same result as the corresponding
embodiments described herein may be utilized according to
the present invention. Accordingly, the appended claims are
intended to include within their scope such processes, compositions of matter, means, methods, or steps.
Each of the references, patents or publications cited herein
is expressly incorporated by reference in its entirety.
What is claimed is:
1. A method of inhibiting, reducing and/or reversing
neovascularization associated with a pathological ocular condition in a mammalian subject, the method comprising the
steps of:
administering a therapeutically effective amount of a pharmaceutical composition to a mammalian subject exhibiting neovascularization associated with a pathological
ocular condition, the pharmaceutical composition comprising cerium oxide nanoparticles and a pharmaceutically acceptable carrier; and
reducing at least one of (a) at least one vascular anomaly,
(b) the number of illicit neovessels, (c) the rate of retinal
neovascularization, and (d) the rate of proliferation of
neovascular tissue in the eye of the mammalian subject
upon administration of the cerium oxide nanoparticles
present in the pharmaceutical composition.
2. The method of claim 1, wherein the at least one vascular
anomaly, the number of illicit neovessels, the rate of retinal
neovascularization, and/or the rate of proliferation of neovascular tissue in the eye of the mammalian subject is substantially reduced to 25% or less of that observed in the absence
of administration of the pharmaceutical composition.
3. The method of claim 1, wherein the at least one vascular
anomaly, the number of illicit neovessels, the rate of retinal
neovascularization, and/or the rate of proliferation of neovas-

cular tissue in the eye of the mammalian subject is substantially reduced to 10% or less of that observed in the absence
of administration of the pharmaceutical composition.
4. The method of claim 1, wherein the at least one vascular
anomaly is selected from the group consisting of retinal
neovascular lesions, choroidal neovascular lesions, choroidal
neovascular tufts, retinal neovascular blebs, and combinations thereof.
5. The method of claim 1, wherein the pathological ocular
condition having neovascularization associated therewith is
at least one of age-related macular degeneration, diabetic
retinopathy, retinitis pigmentosa, retinal detachment, inherited retinal degeneration, Stargardt's disease, and occlusive
retinopathy.
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6. The method of claim 1, wherein the cerium oxide nanoparticles have a size in a range of from about 1 nanometer in
diameter to about 10 nanometers in diameter.
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7. The method of claim 1, wherein the cerium oxide nanoparticles have a size in a range of from about 1 nanometer in
diameter to about 7 nanometers in diameter.
8. The method of claim 1, wherein the cerium oxide nanoparticles are present in the pharmaceutical composition at a
concentration in a range of from about 1 nM to about 1.0 mM.
9. The method of claim 1, wherein the cerium oxide nanoparticles are present in the pharmaceutical composition at a
concentration in a range of from about 1 nM to about 50 nM.

10. A method of treating a mammalian subject having at
least one neovascular lesion in an eye thereof, the method
comprising the steps of:
administering a therapeutically effective amount of a pharmaceutical composition to the eye of the manmialian
subject, the pharmaceutical composition comprising
cerium oxide nanoparticles and a pharmaceutically
acceptable carrier, wherein the cerium oxide nanoparticles have a size in a range of from about 1 nanometer in
diameter to about 10 nanometers in diameter and are
present in the pharmaceutical composition at a concentration in a range of from about 1 nM to about 1.0 mM;
and
reducing the at least one neovascular lesion in the eye of the
mammalian subject to 50% or less of that observed in the
absence of administration of the pharmaceutical composition, and wherein the at least one neovascular lesion
is at least one of a retinal neovascular lesion and a
choroidal neovascular lesion.
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